Chris Viehbacher's efforts to reinvigorate Biogen are continuing to take shape with the appointment of industry veteran Jane Grogan to the position of head of research.
Marie-France Tschudin is stepping down as Novartis' chief commercial officer and president of its innovative medicines group in order to take up another leadership positio
Illumina has appointed Agilent Technologies executive Jacob Thaysen as its new chief executive, following the departure of former CEO Francis deSouza in June and chairman
Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role.
Israeli drugmaker Teva has appointed former Sandoz and Biogen executive Richard Francis to succeed current CEO Kare Schultz, who is scheduled to retire at the end of this year.
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.